ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office (EPO) has issued two new patents to ENDRA, European Patent No. 3668382 (the ‘382 patent) titled “Method and System for Estimating Fractional Fat Content of an Object” and European Patent No. 3661416 (the ‘416 patent) titled “Method for Estimating Fractional Fat Content of an Object.”
- The ‘382 patent protects ENDRA’s method and system for calculating a fat concentration in the human body with a single thermoacoustic measurement. The ‘382 patent is related to U.S. patent 9888879B1 and Chinese patent ZL201880050052.6.
- The ‘416 patent protects ENDRA’s method for calculating a fat concentration in the human body with multiple thermoacoustic measurements. The ‘416 patent is related to U.S. patent 9888880B1 and Chinese patent ZL201880050042.2.
“These two European patents further strengthen our intellectual property estate and advance our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems with our proprietary TAEUS® technology in areas with unmet clinical needs,” stated ENDRA’s Chief Executive Officer, Francois Michelon. “We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently stands at 89 assets, which we define as patents issued, filed or in preparation.”
